Infliximab biosimilar is under clinical development by Celltrion and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

Vedolizumab (Entyvio) and infliximab (Remicade) led to mostly similar 1-year outcomes in patients with ulcerative colitis ...

South Korea’s Celltrion Healthcare has begun a UK trial of its infliximab biosimilar to see if the drug can accelerate recovery from symptoms of COVID-19. The company noted that COVID-19 is ...

Patients with Crohn's disease who lose some or all of their initial therapeutic response to infliximab can benefit from dose intensification. Regueiro et al. retrospectively analyzed 293 patients ...

The success of infliximab paved the way for the introduction of other drugs with a similar mechanism of action. Three other TNF-blocking agents (etanercept, adalimumab and certolizumab pegol) are ...

The top 5 biosimilar conference articles in 2024 highlight significant progress in the biosimilar landscape, including ...

ORLANDO -- Major cardiovascular event risk in patients with inflammatory bowel disease (IBD) was no greater with Janus kinase ...

Acclaimed crime novelist Christie Newport has triumphed over adversity to realise her dream - but is now facing a life-threatening battle due to the withdrawal of a vital treatment.